AbbVie raises 2026 EPS guidance, posts Q3 revenue gain, advances pipeline
Quarterly growth came alongside the closed Apogee Therapeutics deal, new FDA approvals for Skyrizi and Juvmo, and positive late-stage data in HS and DLBCL.
SEC filing (5)
Latest
Thursday, November 5
Arcturus reports Q3 2026 results, CF enrollment nears completion, OTC program advances
Arcturus said ARCT-032 Phase 2 enrollment should finish by year-end with data in Q2 2027, while ARCT-2601 Phase 2 dosing is planned for Q1 2027.
SEC filing (2)
Gilead posts ARTISTRY-2 results; registers GS-1179 herpes trial and ARTISTRY-3 HIV study
Oncolytics details REO 033 colorectal trial design ahead of ESMO presentation
The company said the randomized Phase 2 study aims to confirm the efficacy signal seen in an earlier pelareorep trial in second-line MSS colorectal cancer.
SEC filing (4)
Eton posts record Q3 revenue, raises 2026 guidance, advances rare disease pipeline
Eton reported Q3 2026 revenue of $57.9 million and raised full-year revenue guidance to more than $175 million while reporting progress across six pipeline programs.
SEC filing (2)
Ginkgo Bioworks reports Q3 2026 results, announces first autonomous lab sale to Novo
Ginkgo said third-quarter revenue fell 6% to $28 million while losses narrowed, and disclosed an autonomous lab sale to Novo along with new government contracts.
SEC filing (2)
FDA grants second orphan drug designation to Hutchmed's sovleplenib, this time for AIHA
The November 5, 2026 designation covers autoimmune hemolytic anemia, weeks after a similar designation for immune thrombocytopenia.
SEC filing (2)
Valion Bio's CFO and president Lisa Wolf to resign as Entolimod study advances
Wolf will leave her roles as president, COO, and CFO effective December 11, 2026, as Valion awaits early-December results from a government-funded Entolimod efficacy study.
SEC filing (2)
Regeneron-linked TOP2201 posts results; NeoSTOP-IT terminated, DEUTERON completed
Wednesday, November 4
Neogen updates timeline on Zoetis genomics sale amid antitrust review
Neogen said regulatory clearance for its genomics business sale to Zoetis is now expected to conclude in early 2027 after Zoetis offered to divest assets in Australia.
SEC filing
Oncolytics reports HPV immune activity data for pelareorep in anal cancer
The company said translational data from an ongoing Phase 1/2 study show pelareorep boosts HPV-specific immune responses alongside tumor shrinkage in second-line or later anal cancer patients.
SEC filing
Lyell reports Q3 2026 results, new ronde-cel data headed to ASH
Lyell Immunopharma plans to present updated PiNACLE and Phase 1/2 ronde-cel data at ASH 2026, while keeping its mid-2027 pivotal data and BLA timeline intact.
SEC filing
Myriad Genetics to sell Prenatal Health unit to Labcorp, raises revenue guidance
The company signed a definitive deal to divest Prenatal Health to Labcorp for $210 million in cash plus inventory value, expected to close by early 2027, while nudging up full-year 2026 revenue guidance.
SEC filing
Cidara/Merck Phase 1 trial tests MK-1406 with Fluzone HD vaccine, recruiting
Edgewise reports Q3 2026 results, confirms EDG-7500 Phase 3 to start by year-end
Edgewise said it remains on track to begin a Phase 3 trial of EDG-7500 in hypertrophic cardiomyopathy by the end of 2026 and has dosed its first patient in a Phase 2 heart failure study of EDG-15400.
SEC filing
Cardiff Oncology posts results for terminated onvansertib pancreatic cancer trial
Schrodinger raises 2026 ACV and drug discovery revenue guidance in Q3 results
The company also disclosed it has not started a planned SGR-1505 combination study despite language in an ASH abstract, and flagged strategic options for the program.
SEC filing
Design Therapeutics expands at-the-market stock sale program to $200 million
The company filed a prospectus supplement raising its Jefferies-run equity sales ceiling from $100 million to $200 million, having already sold over $66 million in shares.
SEC filing
GRI Bio holds 2026 annual meeting, re-elects two directors
Stockholders approved an increase to the company's equity incentive plan and ratified its auditor at the November 4 virtual meeting.
SEC filing
Tevogen board shrinks to five after director Susan Podlogar resigns
Podlogar stepped down effective November 2, 2026, and the board named Lindee Goh to the Audit Committee the same day.
SEC filing
Vaxcyte reports positive OPUS-1 topline data for VAX-31, outlines BLA path to first half of 2028
The company says VAX-31 met all primary endpoints in its pivotal adult Phase 3 trial, with pro forma cash of about $3.4 billion after October financings.
SEC filing
Medicus Pharma signs non-binding LOI for SkinJect SPAC combination
The proposed deal values SkinJect at about $135 million and would fund an NDA-enabling study in Gorlin syndrome patients.
SEC filing
Evolus reports Q3 2026 revenue up 13%, reaffirms 2026 and 2028 outlooks
Evolus posted a fourth straight quarter of positive adjusted EBITDA and said it still expects FDA approval of Evolysse Sculpt by year-end 2026.
SEC filing
Cytokinetics posts Q3 2026 results, plans nHCM filing for aficamten in Q4
The company reported $44.5 million in MYQORZO net product revenue and said it expects to submit a supplemental approval application for aficamten in non-obstructive HCM before year end.
SEC filing
Adaptive Biotechnologies posts Q3 profitability, raises full-year MRD revenue guidance
The company reported adjusted EBITDA of $14.3 million for the quarter and lifted its 2026 MRD revenue outlook to $276 million to $286 million, citing new myeloma testing guidelines.
SEC filing
Jazz posts Phase 2 results for zanidatamab combo in GI cancers; JZP269 trial recruits
Acadia reports Q3 2026 results, Phase 3-enabling data for remlifanserin in Alzheimer's psychosis
Acadia raised full-year DAYBUE sales guidance and reported positive Phase 2 RADIANT results supporting Phase 3 development of remlifanserin in Alzheimer's disease psychosis.
SEC filing
BioStem completes BR-AC venous ulcer trial; Kardigan finishes KATALYST-AV aortic stenosis enrollment
Tenaya reports Q3 2026 results, RMAT designation for TN-401, pivotal trial updates due by year end
Tenaya's heart disease gene therapies TN-201 and TN-401 are nearing regulatory decision points, with cash guided into the fourth quarter of 2027.
SEC filing
Innovent registers Phase III trial testing sintilimab in rectal cancer total neoadjuvant therapy
Phibro Animal Health holds fiscal 2027 outlook after first-quarter beat
Phibro reported higher first-quarter sales and profit and left its full-year guidance unchanged, citing a cautious stance on virginiamycin sales in Brazil pending regulatory approvals.
SEC filing
Quoin Pharmaceuticals sets up at-the-market ADS sales deal with Leerink Partners
The company, incorporated in Israel with principal offices in Ashburn, Virginia, can sell American Depositary Shares through Leerink Partners under a November 4, 2026 agreement.
SEC filing
Design Therapeutics reports Q3 2026 results, FA registrational update due in Q4
The company says a Friedreich ataxia regulatory plan update is coming this quarter, with 12-week trial data to follow in early 2027.
SEC filing
Rallybio stockholders approve Avenzo merger, name change, and reverse split
At a November 4, 2026 annual meeting, Rallybio shareholders cleared all eight proposals tied to the Avenzo Therapeutics merger, which the company expects to close November 6, 2026.
SEC filing
Bio Green Med Solution gets Nasdaq bid price deficiency notice
The company has until April 27, 2027 to lift its share price back above $1.00 or face possible delisting from Nasdaq's Capital Market.
SEC filing
Evommune licenses VAV1 degrader EVO570 from Hinova, raises $30M
Evommune will pay up to $1.1 billion in milestones for rights to the oral autoimmune drug candidate outside Greater China, alongside a same-day private placement.
SEC filing
GRAIL reports Q3 2026 results as FDA panel backs Galleri approval
An FDA advisory panel voted in favor of the Galleri multi-cancer test in September, with GRAIL saying it expects a decision by early Q1 2027.
SEC filing
IM Cannabis closes $1.2 million convertible note financing with institutional investor
The Israel-focused medical cannabis company issued a convertible note and matching warrant to an existing investor on November 4, 2026.
SEC filing
Nature's Sunshine cuts 2026 sales and EBITDA outlook after weak third quarter
The supplement maker blamed China disruptions and a stronger dollar as third-quarter net sales fell 9% and full-year guidance was lowered.
SEC filing
Arcutis Biotherapeutics sets up $200 million at-the-market stock offering
The dermatology company filed a prospectus supplement on November 4, 2026 allowing it to sell up to $200 million of common stock through TD Cowen over time.
SEC filing
Ensysce Biosciences discloses CEO transition and board departure plan
Dr. Lynn Kirkpatrick will shift from CEO to COO after the December 14, 2026 annual meeting as director Will Chang plans to resign from the board.
SEC filing
Annovis Bio discloses preliminary cash of $2.8 million as of September 30, 2026
The company's 8-K contains no pipeline or regulatory updates, only a preliminary, unaudited cash figure for the third quarter.
SEC filing
Dianthus reports Q3 2026 results, CIDP interim data and MMN enrollment ahead of schedule
CAPTIVATE's Part A showed a 75% response rate in CIDP, and Dianthus says it holds about $1.2 billion in cash, projected to last into 2030.
SEC filing (2)
Innoviva's IST unit posts 45% U.S. sales growth as NUZOLVENCE launches
Innoviva reported third-quarter 2026 results on November 4, with its specialty therapeutics business on track to meet 2026 guidance and a newly launched gonorrhea antibiotic.
SEC filing
Corner Therapeutics files Form D for $48.3 million equity offering tied to AI3 Bio merger
The filing shows the offering followed a merger transaction and lists eight investors who have already put in money, with the full amount sold.
SEC filing (2)
Alpha Teknova raises 2026 revenue guidance after record third quarter
Teknova reported 22% revenue growth for the quarter and lifted its full-year revenue outlook to $46-48 million after closing a $46 million stock offering in October.
SEC filing